Consent Decree Approved Among the U.S. and Cumberland, M.D. based Pharmacy and Pharmacist
Skip to main content
U.S. flag

An official website of the United States government

Here’s how you know

Dot gov

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Https

Secure .gov websites use HTTPS
A lock ( Lock A locked padlock ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

  • Who We Are
    • About
    • Mission
    • History
    • Divisions
      • Domestic Divisions
      • Foreign Divisions
      • Operational Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
      • Submit a Tip
      • Extortion Scam
      • Public Affairs
      • Social Media Directory
  • What We Do
    • Forensic Sciences
      • GUARDS
      • Forensic Sciences Policy
      • Forensic Science Organizations
      • Forensic Science Contact
    • Law Enforcement
      • DEA Office of Training
        • Office of Training Programs
      • El Paso Intelligence Center (EPIC)
      • Intelligence
      • Operations
        • Administrative Law Judges
        • DEA Asset Forfeiture
        • Domestic Cannabis Suppression / Eradication Program
        • HIDTA
        • OCDETF
    • Education and Prevention
      • Family Summit
      • Red Ribbon
      • Kiki and the History of Red Ribbon Week
      • Red Ribbon Toolkit - Resources For Your Community
      • DEA’s Family Summit
      • Operation Engage
      • Community Outreach
      • Just Think Twice
      • Campus Drug Prevention
      • Get Smart About Drugs
      • Operation Prevention
    • Drug Information
      • Drug Policy
      • Drug Scheduling
      • The Controlled Substances Act
    • News
      • Alerts
      • Press Releases
      • Most Wanted Fugitives
        • All Fugitives
      • Stories
      • Events
      • Speeches
      • Testimony
    • Campaigns
      • One Pill Can Kill
        • Senior Citizens
        • Partner Toolbox
        • Social Media Campaign
      • DEA National Prescription Drug Take Back Day
  • Careers
    • Special Agent
      • Special Agent FAQs
    • Diversion Investigator
      • Diversion Investigator Job Announcement
    • Intelligence Research Specialist
      • Intelligence Research Specialist Job Announcements
      • Intelligence Research Specialists FAQs
      • Schedule A Hiring Authority: Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
      • How To Claim Veterans' Preference
      • Priority Consideration
      • Benefits
      • Veterans and People With Disabilities
      • Operation Warfighter
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
      • Domestic Arrests
      • Staffing and Budget
    • FOIA
      • About FOIA
      • Contact DEA FOIA
      • Make a Request
      • What Happens After Making a Request
      • Requester Categories
      • Fees Charged
      • Fee Waiver
      • FOIA FAQ
      • FOIA Logs and Reports
      • FOIA Library
      • Additional FOIA Links
      • FOIA Exemptions
      • What Are Exclusions?
      • Privacy Act
      • Privacy Act Exemptions
      • Privacy Impact Assessment and Management Information Systems
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
      • Victim Witness Assistance Program Resources
      • Human Trafficking Prevention

United States Drug Enforcement Administration

  • Get Updates
  • Scam Alert
  • Full Menu
  • English
  • Español

Main Menu

Explore DEA
  • Who We Are
    • About
    • Mission
    • History
    • Divisions
    • DEA Museum
    • Wall of Honor
    • Contact Us
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Education and Prevention
    • Drug Information
    • News
    • Campaigns
  • Careers
    • Special Agent
    • Diversion Investigator
    • Intelligence Research Specialist
    • Forensic Sciences Careers
    • Professional & Administrative Careers
    • Student & Entry Level Careers
    • Employment Eligibility
    • How to Apply
  • Resources
    • Illegal Online Pharmacies
    • OD Justice
    • Fentanyl Supply Chain
    • Pill Press Resources
    • Recovery Resources
    • Together for Families
    • Data and Statistics
    • FOIA
    • Publications
    • Media Galleries
    • Victim Witness Assistance Program
  • Submit A Tip

Breadcrumb

  • Home
  • Consent Decree Approved Among the U.S. and Cumberland, M.D. based Pharmacy and Pharmacist

Consent Decree Approved Among the U.S. and Cumberland, M.D. based Pharmacy and Pharmacist

July 06, 2023
|
Share Article
|
Download Press Release
For Immediate Release
Contact: Public Information Office
Phone Number: (571) 362-1934

United States Alleges that the Defendants Ignored Indications that Prescriptions were not Legitimate, including that the Dosage Level or Combination of Drugs Greatly Increased the Risk of Overdose

Baltimore, Maryland - U.S. District Judge Lydia K. Griggsby approved the United States’ consent decree with John A. Beckman, a Cumberland, Maryland based pharmacist, and Beckman’s Greene Street Pharmacy, Inc. (“Beckman’s Pharmacy”), resolving the United States’ civil allegations that Beckman and Beckman’s Pharmacy violated the Controlled Substances Act (“CSA”) in illegally dispensing controlled substances.

The consent decree was announced by United States Attorney for the District of Maryland Erek L. Barron; Principal Deputy Assistant Attorney General Brian M. Boynton, of the Justice Department’s Civil Division; and Special Agent in Charge Jarod A. Forget of the Drug Enforcement Administration – Washington Division.

“Irresponsible pharmacies and pharmacists fan the flames of the ongoing opioid epidemic,” said U.S. Attorney Erek L. Barron.  “Our office intends to use all tools at our disposal—criminal and civil—to hold accountable those at every step in the supply chain who violate the CSA.”

“Pharmacies and pharmacists have an obligation to help stop the illegal distribution of controlled substances,” Principal Deputy Assistant Attorney General Brian M. Boynton, head of the Justice Department’s Civil Division. “The department will work with its law enforcement partners to hold responsible those who dispense potentially dangerous prescription drugs in violation of the law.”

“The devastating effects of opioid overdoses and poisonings have affected many lives in our local communities,” said Special Agent in Charge Jarod Forget for the DEA Washington Division. “Healthcare providers have a great responsibility as it relates to dispensing medications to meet the health needs of our citizens. This includes being vigilant for any signs of controlled substance diversion or misuse. Our team is committed to protecting the safety and health of all Americans, which includes ensuring that all licensed professionals comply with the law and report dangerous behaviors.”

The Government alleges that at least since 2017, Beckman and Beckman’s Pharmacy knowingly filled fraudulent prescriptions for controlled substances, ignoring red flags that should have acted as warning signs that the prescriptions were not legitimate.  More specifically, the Government alleges that, since at least 2017, Beckman and Beckman’s Pharmacy would often dispense dangerous combinations of controlled substances which are known to be pursued by drug abusers, but which seriously increase the risk of respiratory distress, overdose, and death, and did so without noting any reasonable explanation for these dangerous combinations.  These combinations included the extremely dangerous “holy trinity,” which combines an opioid, a benzodiazepine, and carisoprodol.  Additionally, Beckman and Beckman’s Pharmacy often dispensed a combination of an opioid and buprenorphine, a drug which is generally used to treat opioid dependence and regularly filled prescriptions for controlled substances that were paid for with cash even though the patient had insurance available to pay for the patient’s prescriptions. 

The Centers for Disease Control and Prevention generally recommends that individuals should avoid daily dosages of opioids over 90 morphine milligram equivalents (MME), but Beckman and Beckman’s Pharmacy routinely dispensed prescriptions to patients causing their MME levels to be many times that amount—and upwards of 1000 daily MME.  The Government alleges that Beckman and Beckman’s Pharmacy dispensed opioids to more than ten patients who subsequently died within ten days of the date of the prescription for those opioids. 

Under the consent decree, Beckman and Beckman’s Pharmacy agree to pay a $120,000 civil monetary penalty and are required to identify certain red flags—including when a patient has traveled a long distance to the pharmacy, and when a patient is receiving an opioid and a benzodiazepine.  Before filling prescriptions bearing those and other red flags, the consent decree requires Beckman and Beckman’s Pharmacy to document in detail any indications of abuse or diversion and the steps they took to ensure that the prescription was valid and was issued for a legitimate medical purpose, and that the prescription would not be abused or diverted for illegitimate purposes.  Additionally, under the consent decree, Beckman and Beckman’s Pharmacy are prohibited from filling certain prescriptions, including when a patient presents prescriptions that, if filled, would cause the patient to take more than 90 daily MME; a combination of an opioid, a benzodiazepine, and carisoprodol; most prescriptions for buprenorphine without naloxone; any controlled substance paid for with cash even though the patient has insurance available to pay for the patient’s prescriptions; and any prescription for a controlled substance if the patient is an employee of Beckman’s Pharmacy.

Under the consent decree, if the DEA determines that Beckman or Beckman’s Pharmacy have violated any provision of the consent decree or if Beckman or Beckman’s Pharmacy do not implement the corrective action the DEA orders, the DEA can order Beckman and Beckman’s Pharmacy to cease ordering or dispensing controlled substances immediately. 

The consent decree is not an admission of liability by Beckman or Beckman’s Pharmacy, nor a concession by the United States that its claims are not well founded.   

The Court’s approval of this consent decree—the fourth such consent decree in the District of Maryland in the past two years—should again remind pharmacists and pharmacies of their corresponding responsibility to confirm the legitimacy of the prescriptions that they fill and that the Department of Justice intends to use all tools at its disposal—both criminal and civil—to combat the controlled substances epidemic which continues to plague our country, including here in Maryland. 

U.S. Attorney Erek L. Barron and Principal Deputy Assistant Attorney General Brian M. Boynton commended the DEA Baltimore Division’s Office of Diversion Control and Tactical Diversion Squad for its work in the investigation.  Mr. Barron and Mr. Boynton thanked Assistant United States Attorney Alan C. Lazerow and Donald R. Lorenzen, Senior Litigation Counsel with the Department of Justice’s Consumer Protection Branch, who handled the case.

District of Maryland | Consent Decree Approved Among the United States and Cumberland, Maryland Based Pharmacy and Pharmacist Alleged to Have Illegally Dispensed Controlled Substances | United States Department of Justice

Download Press Release
###
Opioids Benzodiazepines
US Department of Justice - Drug Enforcement Administration

Drug Enforcement Administration

Ibrar A. Mian Special Agent in Charge - Washington, DC
@DEAWashingtonDC
  • Facebook
  • X
  • Email

SAMHSA Behavioral Health Treatment Locator

  • Who We Are
    • About
    • Domestic Divisions
    • Foreign Offices
    • Contact Us
    • DEA Museum
  • What We Do
    • Forensic Sciences
    • Law Enforcement
    • Drug Prevention
    • Diversion Control Division
    • News
  • Careers
    • Special Agent
    • Diversion Investigator
    • Forensic Sciences
    • Intelligence Research Specialist
    • How to Apply
  • Resources
    • Drug Information
    • Employee Assistance Program
    • FOIA
    • Publications
    • Media Galleries
    • VWAP
  • Doing Business
    with the DEA
    • Overview
    • Current Vendors
    • Prospective Vendors
    • Security Clauses
    • Security Forms
    • Small Business Program
    • Vendor Engagement Request
  • Policies
    • Accessibility & Policy
    • Legal Policies & Disclaimers
    • No FEAR Act
    • Privacy Policy
    • U.S. Department of Justice EEO Policy
    • USA.gov
    • Whistleblower Protection
    • Your Rights as a Federal Employee

United States Drug Enforcement Administration

DEA.gov is an official site of the U.S. Department of Justice
Facebook X LinkedIn Instagram

DEA Contact Center

(202) 307-1000 info@dea.gov
Contact the Webmaster